SEC Tracker
Get the app
RLYB · XBRL financial data

Rallybio financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (RLYB's year ends in late December)

In thousands of dollarsDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024†Dec 31, 2025
Revenue———600858
Research and development26,90940,68953,54441,50719,597
General and administrative18,73927,19525,38819,62514,325
Total operating expenses45,64867,88478,93261,13233,922
Operating income (loss)(45,648)(67,884)(78,932)(60,496)(33,064)
Interest expense100———
Other income (expense)9634226274422,771
Income tax expense (benefit)00000
Net income (loss)(47,013)(66,654)(74,564)(57,775)(8,978)
Earnings per share, basic USD per share(1.84)(2.09)(1.84)(1.33)(1.59)
Earnings per share, diluted USD per share(1.84)(2.09)(1.84)(1.33)(1.59)
Weighted average shares, basic thousands of shares25,51931,82140,44743,5455,629
Weighted average shares, diluted thousands of shares25,51931,82140,44743,5455,629
  • † Share count changed about 1/8 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal years (RLYB's year ends in late December)

In thousands of dollarsDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024†Dec 31, 2025
Cash and cash equivalents175,33456,95824,49413,90331,374
Marketable securities0112,03685,43551,60823,362
Prepaid and other current assets5,53510,5024,8602,3306,517
Total current assets180,869179,496114,78967,84161,253
Property and equipment, net51138524611523
Right-of-use asset700524346152175
Total assets182,185180,435115,62068,10862,261
Accounts payable6031,114976278126
Accrued liabilities5,9489,4498,0684,9623,791
Total current liabilities6,55110,7449,2636,2424,223
Lease liability, non-current0374173082
Total liabilities6,58311,1189,4366,4544,305
Accumulated deficit(94,027)(160,681)(235,245)(293,020)(301,998)
Total stockholders' equity175,602169,317106,18461,65457,956
Total liabilities and equity182,185180,435115,62068,10862,261
Common shares outstanding (cover page) thousands of shares32,13138,07537,81241,6125,290
  • † Share count changed about 1/8 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal years (RLYB's year ends in late December)

In thousands of dollarsDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024†Dec 31, 2025
Net income (loss)(47,013)(66,654)(74,564)(57,775)(8,978)
Stock-based compensation3,6459,49910,9207,9935,314
Net cash from operating activities(45,533)(57,284)(60,265)(49,282)(29,813)
Purchases of property and equipment33354120—
Net cash from investing activities(2,333)(112,170)27,65833,49247,268
Proceeds from issuing common stock0—05,4050
Net cash from financing activities82,96751,0781435,19916
Net change in cash—(118,376)(32,464)(10,591)17,471
  • † Share count changed about 1/8 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Rallybio90,6930(2,276)*5.4M— 10-QSep 30, 2026
Brainstorm Cell Therapeutics22not reported(895)11.0M0.0 quarters 10-QJun 30, 2026
Kiora Pharmaceuticals7,077not reported(1,892)*4.4M8.9 quarters 10-QJun 30, 2026
Scienture Holdings8,188344(3,132)*41.1M2.6 quarters 10-QJun 30, 2026
Phio Pharmaceuticals10,609not reported(2,280)*12.0M3.1 quarters 10-QSep 30, 2026
Palisade Bio125,172500(7,603)*174.3M16.5 quarters 10-QJun 30, 2026
LeonaBio32,323not reported(16,958)*9.4M3.0 quarters 10-QJun 30, 2026
Mannatech6,03426,650(792)*1.9M7.6 quarters 10-QJun 30, 2026
Citius Pharmaceuticals17,0081,494(8,678)*27.5M2.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.